Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
The only definitive way to diagnose and stage lung cancers is through biopsies
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Innate to receive $5M milestone payment from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
